



South Sudan

Support for Vaccine: Measles

This Decision Letter sets out the Programme Terms of a Programme

1. **Country:** South Sudan

2. **Vaccine grant number:** SSD-M-C-FU

3. **Date of Decision Letter:** 12 December 2022

4. **Date of the Partnership Framework Agreement:** 24 June 2013

5. **Programme title:** New Vaccine Support (NVS), Measles, Follow-up campaign

6. **Vaccine type:** Measles

7. **Requested product presentation and formulation of vaccine:**

M, 10 doses/vial, lyophilised

8. **Programme duration:**¹ 2019-2023

9. **Programme Budget (indicative):**² (subject to the terms of the Partnership Framework Agreement, if applicable)

	2019-2021	2022	2023	2024	2025	2026	Total ³
Programme Budget(US\$)	988,434	-	1,518,083	-	-	-	2,506,517

10. **Vaccine introduction grant:**

Not applicable

11. **Product switch grant:**

Not applicable

¹This is the entire duration of the programme.

²This is the total amount endorsed by Gavi for the entire duration of the programme.

Starting January 2020, a separate Decision Letter for devices only, including historical value of devices will be discontinued. Vaccine programme decision letters issued since January 2020 contain associated devices, however devices in relation to years prior to 2020 are no longer included in decision letters.

³This is the amount that Gavi has approved.



12. Indicative annual amounts:³ (subject to the terms of the Partnership Framework Agreement, if applicable)

Type of supplies to be purchased with Gavi funds	2019-2021	2022	2023
Number of vaccine doses	-	-	3,022,500
Number of AD syringes	-	-	3,056,600
Number of re-constitution syringes	-	-	339,300
Number of safety boxes	-	-	33,975
Annual Amounts (US\$)	988,434	-	1,518,083

13. Procurement agency: UNICEF Supply Division. The Country shall release its co-financing payments each year to UNICEF Supply Division.

14. Self-procurement:

Not applicable

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group:			Initial self-financing		
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.					
Type of supplies to be purchased with Country funds in each year	2022	2023	2024	2025	2026
Number of vaccine doses	-	62,000	-	-	-
Number of AD syringes	-	-	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	-	-	-	-	-
Value of vaccine doses (US\$)	-	23,870	-	-	-
Total co-financing payments (US\$) (including freight)	-	26,282	-	-	-

16. Operational support for campaigns:

Year	Grant number	Amount (US\$)
2019	SSD-M-C-FU-OPS-UNIC	1,137,134
2019	SSD-M-C-FU-OPS-WHO	2,288,048
2023	SSD-M-C-FU-OPS	2,809,128

17. Additional Reporting Requirements:



Reports and other information :	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: ● vaccine stock levels including buffer stock, by end of March; ● number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. ● Countries shall report the actual switch date in the first renewal request following the actual implementation.	31 March 15 May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
To report on national and sub-national programmatic readiness using the WHO Readiness Assessment Tool (or equivalent) at the recommended time points.	Starting 15 months prior to campaign date, up to 1 week before the campaign, at the recommended time points of the tool.
To submit the Supplementary Immunisation Activity (SIA) technical report for Measles or Measles-Rubella campaign.	Within 3 months of end of campaign.
To submit the Post campaign coverage survey report for Measles or Measles-Rubella campaign.	As soon as available.

18. Financial clarifications:

Not applicable

19. Other conditions:



As a condition to Gavi's support for measles and rubella, country will be required to fully self-finance with domestic resources the measles component of the first dose of measles containing vaccine (MCV1) in its national immunisation programme for 2018 and onwards.

	2022	2023	2024	2025	2026
Minimum number of doses to be financed from domestic resources	-	-	-	-	-
Minimum amount to be financed from domestic resources (US\$)	-	-	-	-	-

DocuSigned by:
Amy LaTrielle
 62F489252BB7466...

Amy LaTrielle

Director, Fragile and Conflict Countries